Theradiag obtains CE mark for proprietary anti-CCP IVD kit in rheumatoid arthritis

Theradiag (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostic and in vitro diagnostics, today announced it has obtained a CE mark for its proprietary anti-CCP in vitro diagnostic (IVD) kit in rheumatoid arthritis. This test further expands the Fidis portfolio of diagnostic tests for auto-immunes diseases, which significantly decreases costs and time of analysis thanks to the Multiplex technology. Fidis is the most complete multiplex range of diagnostics currently marketed.

This new way of detecting anti cyclic citrullinated peptides (anti-CCPs) antibodies allows for highly-reliable detection of severe forms of RA through a more rapid dosing and at a lower cost than existing tests.

"This new CE mark shows our ability to further expand our high-value IVD portfolio. With this new addition to the Fidis range, we position ourselves as testing and monitoring leaders in auto-immune and inflammatory diseases. This anti-CCP test strengthens our in house products portfolio, in line with our development strategy. The new kits will be available internationally, like all our other Fidis products" commented Michel Finance, CEO of Theradiag.

The new anti-CCP test is the third proprietary diagnostic kit of Theradiag to obtain a CE mark this year. The auto-immune diseases segment grew strongly in 2012 (+17% for Fidis products), making-up for 43 percent of company sales in 2012.

SOURCE Theradiag

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
New guideline for juvenile idiopathic arthritis gives emphasis to disease-modifying treatments